Trial Profile
A Single-Center, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine (RBP-6000) Using Poly (DL-lactide-co-glycolide) Polymer of Two Different Molecular Weights (Low and High Molecular Weights as Test Treatments) in Comparison to Intermediate Molecular Weight (Reference Treatment) in Treatment-Seeking Subjects With Opioid Use Disorder
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Buprenorphine/naloxone (Primary)
- Indications Opioid-related disorders
- Focus Pharmacokinetics
- Sponsors Indivior; Reckitt Benckiser
- 22 Feb 2019 Results assessing the effects of a monthly buprenorphine depot subcutaneous injection on QT interval during treatment for opioid use disorder in 1114 subjects pooled from 5 studies (RB-US13-0001, RB-US10-0011, RB-US11-0020, RB-US12-0005, RB-US13-0006) published in the Clinical Pharmacology and Therapeutics
- 12 May 2016 Status changed from active, no longer recruiting to completed.
- 10 May 2016 Status changed from recruiting to active, no longer recruiting.